17. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving TAB001;
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study therapy.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study treatment
Receipt of live attenuated vaccination within 30 days prior to the first dose of Vicinium or durvalumab
Receipt of live attenuated vaccination within 30 days prior to first anticipated dose of nivolumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab.
Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab, or active infection
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab OR tremelimumab.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry (or due to receive one within 30 days of receiving either MEDI4736 or tremelimumab)
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 6 months of receiving MEDI4736 or MEDI + tremelimumab
Receipt of live attenuated vaccination within 30 days prior to registration; NOTE: patients should also not receive such vaccination within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to receiving MEDI4736
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days after receiving the last dose of durvalumab.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days prior to study entry
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Receipt of live attenuated vaccination within 30 days prior to step 1 registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to first dose of MEDI4736
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted